Clinical Trials Logo
  1. Home
  2. Choroidal Melanoma
  3. NCT01251978

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

Choroidal Melanoma Clinical Trial

Official title:
Phase 2 Study to Evaluate the Efficacy of High Dose Ranibizumab as Adjuvant in the Treatment of Choroidal Melanoma

Clinical Trial Summary

Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that might be needed to control the tumor.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01251978
Study type Interventional
Source New England Retina Associates
Contact
Status Completed
Phase Phase 2
Start date July 2010
Completion date August 2012
View Details
See also
  Status Clinical Trial Phase
Completed NCT00680225 - Lucentis as an Adjuvant Therapy With TTT-ICG Based in Choroidal Melanoma Phase 3
Completed NCT00750399 - Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma Phase 1
Recruiting NCT03941379 - A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
Completed NCT02875652 - Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU) N/A
Completed NCT00765921 - Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma Phase 1
Completed NCT00351728 - Combined PET/CT Imaging for the Early Detection of Ocular Melanoma Metastasis Compared to CT Scanning Alone N/A
Completed NCT01460810 - Safety and Efficacy of Silicone Oil Tamponade for Surgical Attenuation of Radiation Damage in Choroidal Melanoma N/A
Completed NCT00344799 - Cytogenetic Study of Ocular Melanoma
Completed NCT01253759 - Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma Phase 4
Completed NCT03052127 - Study in Subjects With Small Primary Choroidal Melanoma Phase 1/Phase 2
Active, not recruiting NCT00111046 - Pain Relief - Tramadol Versus Ibuprofen Phase 1/Phase 2
Recruiting NCT06007690 - A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma Phase 3
Active, not recruiting NCT04417530 - Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma Phase 2
Terminated NCT05266430 - Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)